Overview

* Fate Therapeutics Q3 2025 revenue was $1.7 mln, a decrease from the previous year

* Net loss for Q3 2025 was $32.25 mln, increasing Y/Y

Outlook

* Company projects operating runway through 2027 with $226 mln in cash and investments

* Fate Therapeutics ( FATE ) plans registration study for FT819 in 2026

* Company receives UK and EU regulatory authorization for FT819 clinical trials

Result Drivers

* REGULATORY AUTHORIZATIONS - Fate Therapeutics ( FATE ) received authorization from UK and EU authorities to activate ex-US clinical trial sites for FT819, expanding international reach

* AUTOIMMUNE DISEASE TRIALS - FT819 showed promising clinical activity and safety in autoimmune diseases, including lupus and systemic sclerosis, with reduced conditioning requirements

* SOLID TUMOR PROGRAM - FT836 targets solid tumors using Sword and Shield technology, enabling conditioning-free treatment

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $1.74

Collabor mln

ation

Revenue

Q3 Net -$32.25

Income mln

Q3 Basic -$0.27

EPS

Q3 -$34.74

Income mln

from

Operatio

ns

Q3 $36.48

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Fate Therapeutics Inc ( FATE ) is $4.50, about 76.9% above its November 12 closing price of $1.04

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)